Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients

Heart and Vessels

Volumn 26, Issue 3, 2011, Pages 252-257

  Wakabayashi, Kana ^a   Tsujino, Takeshi ^a   Naito, Yoshiro ^a   Ezumi, Akira ^a   Lee Kawabata, Masaaki ^a   Nakao, Shinji ^a   Goda, Akiko ^a   Sakata, Yasushi ^b   Yamamoto, Kazuhiro ^b   Daimon, Takashi ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Aortic stenosis; Peak aortic valve jet velocity; Statin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; AGED; AORTA PRESSURE; AORTA VALVE; AORTA VALVE STENOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG EFFICACY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PEAK AORTA VALVE JET VELOCITY; PEAK AORTA VALVE PRESSURE GRADIENT; PRESSURE GRADIENT; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTIC VALVE; AORTIC VALVE STENOSIS; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; JAPAN; LINEAR MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 79959754342     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-010-0052-x     Document Type: Article

References (41)

1. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS (1999) Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 341:142-147 (Pubitemid 29325741)
2. Lindroos M, Kupari M, Heikkila J, Tilvis R (1993) Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 21:1220-1225 (Pubitemid 23106200)
3. Chan KL (2003) Is aortic stenosis a preventable disease? J Am Coll Cardiol 42:593-599
4. Novaro GM, Griffin BP (2003) Calcific aortic stenosis another face of atherosclerosis? Clevel Clin J Med 70:471-477
5. Branch KR, O'Brien KD, OttoCM(2002) Aortic valve sclerosis as a marker of active atherosclerosis. Curr Cardiol Rep 4:111-117
6. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD (1994) Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90:844-853
7. Warren BA, Young JL (1997) Calcification of the aortic valve: its progression and grading. Pathology 29:360-368 (Pubitemid 27515488)
8. Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M, Hvass U, Couetil JP, Henin D, Michel JB, Vahanian A, Jacob MP (2005) Extracellular matrix remodeling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 26:1333-1341 (Pubitemid 41435466)
9. Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkilä J, Tilvis R (1994) Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 15:865-870 (Pubitemid 24223943)
10. Pohle K, Mäffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S (2001) Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104:1927-1932 (Pubitemid 32983236)
11. Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR (1997) A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart 78:475-479 (Pubitemid 27515108)
12. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF (1991) Development and progression of aortic valve stenosis: atherosclerosis risk factors-a causal relationship? A clinical morphologic study. Clin Cardiol 14:995-999
13. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM (1997) Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29:630-634 (Pubitemid 27116107)
14. Ngo MV, Gottdiener JS, Fletcher RD, Fernicola DJ, Gersh BJ (2001) Smoking and obesity are associated with the progression of aortic stenosis. Am J Geriatr Cardiol 10:86-90 (Pubitemid 32215684)
15. Palta S, Pai AM, Gill KS, Pai RG (2000) New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 101:2497-2502 (Pubitemid 30366254)
16. Deutscher S, Rockette HE, Krishnaswami V (1984) Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis 37:407-415 (Pubitemid 14134891)
17. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Després JP, Arsenault M, Couet J, Pibarot P (2006) Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol 47:2229-2236 (Pubitemid 43795081)
18. Aronow WS, Ahn C, Kronzon I, Goldman ME (2001) Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88:693-695 (Pubitemid 32831111)
19. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP (2001) Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104:2205-2209 (Pubitemid 33043301)
20. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez- Sarano M (2002) Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment and progression of aortic stenosis in the community. J Am Coll Cardiol 40:1723-1730 (Pubitemid 35341948)
21. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H (2004) Statins but not angiotensin - converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110:1291-1295 (Pubitemid 39202347)
22. Antonini-Canterin F, Popescu BA, Huang G, Korcova-Miertusova R, Rivaben D, Faggiano P, Pavan D, Piazza R, Bolis A, Ciavattone A, Ruggiero A, Nicolosi GL (2005) Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J 6:119-124
23. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 35:22389-22397
24. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F, Rajamannan NM (2007) Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49:554-561 (Pubitemid 46177435)
25. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359:1343-1356
26. O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, Wu AH, Zhao XQ, Budoff MJ (2005) Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 165:858-862 (Pubitemid 40563231)
27. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H (2004) Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110:1291-1295 (Pubitemid 39202347)
28. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.ClinChem 18:499-502
29. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41-50 (Pubitemid 46474965)
30. Naito Y, Tsujino T, Lee-Kawabata M, Matsumoto M, Ezumi A, Nakao S, Goda A, Ohyanagi M, Masuyama T (2009) Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction. Heart Vessels 24:181-186
31. Toggweiler S, Zuber M, Gerber K, Schläpfer R, Erne P, Stulz P (2010) Left ventricular mass regression following implantation of MIRA bileaflet valves in patients with severe aortic stenosis. Heart Vessels 24:37-40
32. Routledge HC, Townend JN (2001) ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity? J Hum Hypertens 15:659-667
33. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE (2001) Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 104:2177-2181 (Pubitemid 33043296)
34. Nikolaidis L, Doverspike A, Huerbin R, Hentosz T, Shannon R (2002) Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism. Circulation 105:2785-2790 (Pubitemid 34615152)
35. Yamamoto D, Takai S, Miyazaki M (2007) Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site. Biochem Biophys Res Commun 354:981-984 (Pubitemid 46216229)
36. Levy BI (2004) Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation 109:8-13
37. O'Brien KD, Shavelle DM, Caulfield MT, McDonald TO, Olin- LewisK,OttoCM, Probstfield JL (2002)Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 106:2224-2230 (Pubitemid 35222217)
38. Helske S, Lindstedt KA, Laine M, Mäyränpää M, Werkkala K, Lommi J, Turto H, Kupari M, Kovanen PT (2004) Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44:1859-1866 (Pubitemid 39424087)
39. Helske S, Laine M, Kupari M, Lommi J, Turto H, Nurmi L, Tikkanen I, Werkkala K, Lindstedt KA, Kovanen PT (2007) Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves. Eur Heart J 28:1894-1903 (Pubitemid 47236647)
40. CharestA, PépinA, ShettyR,Côté C,Voisine P,Dagenais F, Pibarot P, Mathieu P (2006) Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 92:1844-1849 (Pubitemid 44851338)
41. Edep ME, Shirani J, Wolf P, Brown DL (2000) Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 9:281-286